Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.

[1]  S. Madhi,et al.  WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016 , 2016, Vaccine.

[2]  I. Margarit,et al.  The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. Madhi,et al.  Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. , 2016, The Lancet. Infectious diseases.

[4]  S. Madhi,et al.  Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial , 2016, The Lancet. Infectious diseases.

[5]  R. Devlieger,et al.  Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial , 2016, Obstetrics and gynecology.

[6]  S. Madhi,et al.  Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants. , 2015, Vaccine.

[7]  R. Platt,et al.  Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. , 2014, The Journal of infectious diseases.

[8]  V. Allen,et al.  The prevention of early-onset neonatal group B streptococcal disease. , 2013, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[9]  P. Heath,et al.  An overview of global GBS epidemiology. , 2013, Vaccine.

[10]  S. Schrag,et al.  Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. , 2013, Vaccine.

[11]  Kurt Hornik,et al.  The Comprehensive R Archive Network , 2012 .

[12]  I. Margarit,et al.  A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus. , 2012, Journal of immunological methods.

[13]  P. Melin.  Prevention of Perinatal Group B Streptococcal Diseases: Belgian Guidelines , 2007 .

[14]  J. Troendle,et al.  Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. , 2004, The Journal of infectious diseases.

[15]  J. Troendle,et al.  Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. , 2001, The Journal of infectious diseases.

[16]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[17]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[18]  D. Kasper,et al.  Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. , 1979, The Journal of infectious diseases.

[19]  D. Kasper,et al.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.

[20]  F. Barrett,et al.  Transmission of group B streptococci among parturient women and their neonates. , 1973, The Journal of pediatrics.